Abstract
Antonuccio raises a number of interesting and thoughtful points in his letter. These issues, as he implies, are not only relevant in terms of interpreting our work, but, indeed, in interpreting virtually all of the smoking cessation studies published in the medical literature, particularly those using a nicotine reduction medication, eg, nicotine polacrilex, nicotine patch, nicotine nasal spray, or nicotine vapor inhaler. First, in our view, it is appropriate to compare active vs placebo treatment conditions at the same time points from target quit day (TQD) onward. As has been clearly documented over the past 30 years, nicotine is not responsible for the overwhelming majority of the morbidity and mortality produced by tobacco smoke. 1 There is no evidence that either nicotine or its metabolites are carcinogens or co-carcinogens. 1 Rather, the vast majority of cigarette-produced illnesses are created from the other 4000 compounds in tobacco smoke. 1 Thus, from
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
